Monte Rosa Therapeutics Inc. (GLUE)
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GLUE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $738.29M
- EPS (TTM)
- -$1.39
- Dividend yield
- None
- 52-week range
- 8.48 – 25.77
- Day range
- 8.48 – 9.04
- Volume / Avg
- 2.52M / 1.37M
- Beta
- —
- Shares outstanding
- 85.45M
52-week range
GLUE stock today
Monte Rosa Therapeutics (GLUE) closed at $8.64 on Nov 20, down 3.03% (-$0.27), versus the S&P 500's 3.70% decline. Shares are 66.5% below their 52-week high of $25.77, set on Jan 8, 2026 and 1.9% above the 52-week low of $8.48, near the bottom of the past year's range. GLUE is down 44.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.2%.
Monte Rosa Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Monte Rosa Therapeutics
Company profileMonte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Markus Warmuth M.D.
- Headquarters
- Boston, MA
- Employees
- 185
- IPO year
- 2021
- Website
- monterosatx.com
Financial highlights
Full financialsIn fiscal 2025, Monte Rosa Therapeutics generated $123.7 million in revenue, up 63.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Monte Rosa Therapeutics reported a net loss of $38.6 million, compared with a loss of $72.7 million a year earlier. Operating margin was -43.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $123.67M | $75.62M | $0 | — | — |
| Growth | +63.54% | — | — | — | — |
| Net income | $-38.60M | $-72.70M | $-135.35M | $-108.50M | $-73.96M |
| EPS (diluted) | $-0.46 | $-0.98 | $-2.63 | $-2.30 | $-2.96 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$25.38+193.75%
- Strong buy 2
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.03 vs $-0.10
- Surprise
- +130.00%
GLUE news
All GLUE news- Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in GoutGlobeNewswire
- Monte Rosa Therapeutics reports Q3 resultsSeeking Alpha
- Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Monte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock UpNasdaqGLUE, NVS, HEI.A
- Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)GlobeNewswire
Monte Rosa Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs GLUE |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs GLUE |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs GLUE |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs GLUE |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs GLUE |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs GLUE |
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs GLUE |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs GLUE |
Indexes, lists and sector
Monte Rosa Therapeutics stock FAQ
What is Monte Rosa Therapeutics's stock price today?
GLUE last traded at $8.64 as of Nov 20, 4:00 PM EST, down 3.03% on the day. Prices are delayed at least 15 minutes.
Who is Monte Rosa Therapeutics's CEO?
Dr. Markus Warmuth M.D. is the chief executive officer of Monte Rosa Therapeutics Inc., which has about 185 employees.
What is the GLUE 52-week high?
The 52-week high for GLUE is $25.77 and the 52-week low is $8.48. The stock is currently 66.5% below its high.